Psoriatic Arthritis: Symptoms, Diagnosis, Treatment Options, and Living Well
Psoriatic arthritis (PsA) is a chronic inflammatory spondyloarthropathy affecting ~30% of psoriasis patients. It involves peripheral joints, axial skeleton, entheses, skin, nails, and eyes. Early diagnosis and treat-to-target strategy prevent irreversible joint damage.
Clinical Domains (CASPAR Criteria)
- Peripheral arthritis: Asymmetric oligoarthritis, dactylitis (sausage digits), symmetric polyarthritis (RA-like).
- Axial disease: Inflammatory back pain (nocturnal, improves with activity), sacroiliitis.
- Enthesitis: Achilles, plantar fascia, costochondral, pelvic.
- Dactylitis: Diffuse digit swelling (flexor tenosynovitis + synovitis).
- Skin/nail psoriasis: Plaques, pitting, onycholysis, oil spots.
- Extra-articular: Uveitis, IBD, cardiovascular/metabolic comorbidity.
Diagnosis
- CASPAR criteria: Inflammatory articular disease + ≥3 points (current psoriasis=2, personal/family history=1, nail dystrophy=1, dactylitis=1, RF negative=1, juxta-articular bone formation=1).
- Imaging: X-ray (pencil-in-cup, osteolysis, periostitis), US/MRI (synovitis, enthesitis, bone edema – earlier detection).
- Labs: CRP/ESR (elevated 40–50%), RF/anti-CCP negative (usually), HLA-B27 (axial subset).
Treatment: Treat-to-Target (T2T) – Minimal Disease Activity (MDA) or Remission
1. NSAIDs
First-line for mild peripheral symptoms; no disease modification. GI/CV/renal monitoring.
2. Conventional Synthetic DMARDs (csDMARDs)
- Methotrexate (MTX): Anchor drug; 15–25 mg/week + folic acid. Modest skin/joint benefit; limited axial/entheseal efficacy.
- Sulfasalazine, Leflunomide: Alternatives.
3. Biologic DMARDs (bDMARDs) – High Efficacy, Rapid Onset
| Class | Agents | Key Notes |
|---|---|---|
| TNF inhibitors | Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab | Broad domain coverage; first-line biologic; TB screening mandatory |
| IL-17 inhibitors | Secukinumab, Ixekizumab, Brodalumab | Superior skin (PASI 100); caution in IBD |
| IL-23 inhibitors | Guselkumab, Risankizumab, Tildrakizumab | Excellent skin, joint; less IBD risk; quarterly dosing |
| IL-12/23 inhibitor | Ustekinumab | Established; q12 wk dosing |
| CTLA4-Ig | Abatacept | T-cell co-stimulation blockade; IV/SC |
4. Targeted Synthetic DMARDs (tsDMARDs)
- Apremilast (PDE4 inhibitor): Oral; modest efficacy; GI side effects; no lab monitoring.
- JAK inhibitors (Tofacitinib, Upadacitinib): Oral; broad efficacy; boxed warnings (infection, VTE, malignancy, CV events); reserve after bDMARD failure.
5. Local Therapy
- Intra-articular glucocorticoids (flare bridge).
- Enthesis injection (US-guided).
6. Non-Pharmacologic
- Physical/occupational therapy (joint protection, splinting, exercise).
- Weight loss (BMI >25 worsens response).
- Smoking cessation (reduces efficacy, ↑ CVD).
- Cardiometabolic risk management.
Monitoring & Comorbidities
- q3–6 mo: DAPSA/MDA, labs (CBC, LFT, renal), TB screen (annual if biologic).
- Screen: CVD, diabetes, NAFLD, depression, IBD, uveitis (annual ophthalmology).
- Vaccinations: Update pre-biologic; avoid live vaccines.
Pregnancy & PsA
Certolizumab (no placental transfer) preferred. MTX, leflunomide, JAKi contraindicated. Plan with rheumatologist/OB pre-conception.
PsA is manageable. Early rheumatology referral, shared decision-making, and holistic care enable full, active lives.
Tumors - Related Articles
- Hemangioma: Understanding Causes, Symptoms & Treatment
- Peritoneal Mesothelioma: Understanding Symptoms, Treatment & Relief
- Benign Tumors: Understanding Non-Cancerous Growths
- Thyroid Cyst, Nodule, or Tumor Diagnosis: Symptoms & What to Expect
- Understanding Fibroid Shrinkage: Symptoms and Types
- Red Clover and Cancer: Exploring Potential Benefits and Risks
- Prolactinoma Treatment: Understanding Tumor Size Reduction
